SSR125543

a CRF1 receptor antagonist with antidepressant-like effects

Also Known As:

(4-(chloro-4-methoxy-5-methylphenyl)-N-((1S)-2-cyclopropylfluoro-4-methylphenyl)ethyl)5-methyl-N-(2-propynyl)-1,3-thiazamine

Networked: 6 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - SSR125543: 6
- Sulfur Compounds: 278
  - Thiazines: 3
    - SSR125543: 6
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiazines: 3
    - SSR125543: 6

Experts

1.	Griebel, Guy: 3 articles (02/2015 - 05/2011)
2.	Beeské, Sandra: 2 articles (02/2015 - 01/2013)
3.	Belzung, Catherine: 2 articles (02/2015 - 01/2013)
4.	Philbert, Julie: 2 articles (02/2015 - 05/2011)
5.	Belzung, C: 2 articles (07/2013 - 09/2012)
6.	Griebel, G: 2 articles (07/2013 - 09/2012)
7.	Philbert, J: 2 articles (07/2013 - 09/2012)
8.	Dournes, Carine: 1 article (01/2013)
9.	Palme, R: 1 article (09/2012)
10.	Pichat, P: 1 article (09/2012)

Related Diseases

1.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 09/01/2012 - "SSR125543 effects were evaluated in a mouse model of post-traumatic stress disorder. " 02/15/2015 - "The CRF₁ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine." 02/15/2015 - "Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day/i.p.), and the partial N-methyl-d-aspartate (NMDA) receptor agonist, d-cycloserine (10 mg/kg/day/i.p.), two compounds which have demonstrated clinical efficacy against PTSD. " 07/01/2013 - "Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial N-methyl-D-aspartate (NMDA) receptor agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/01/2007 - "Overall, these results suggest that although SSR125543 had relatively mild effects on energy balance, CRF(1) receptor blockade attenuated several metabolic effects of short-term fasting and improved plasma variables related to the metabolic syndrome and diabetes."
3.	Cognitive Dysfunction 07/01/2013 - "The present study aims at investigating whether the effects of SSR125543 (10 mg/kg/day for 2 weeks) on cognitive impairment induced by traumatic stress exposure are associated with changes in hippocampal excitability. " 05/01/2011 - "This cognitive impairment in stressed mice was prevented by the administration of SSR149415 (10 mg/kg, ip), SSR125543 (10 mg/kg, ip) and the selective serotonin reuptake inhibitor, fluoxetine (10 mg/kg, ip). " 05/01/2011 - "The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice."
4.	Treatment-Resistant Depressive Disorder 01/10/2013 - "Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543."
5.	Acute Traumatic Stress Disorders (Acute Stress Disorder) 05/01/2011 - "Together, these data suggest that SSR149415 and SSR125543 may be of interest to reduce the cognitive deficits following exposure to stress-related events, such as acute stress disorder."

Related Drugs and Biologics

1.	Paroxetine (Paxil)
2.	N-Methylaspartate (NMDA)
3.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
4.	Serotonin (5 Hydroxytryptamine)
5.	Cycloserine (Seromycin)
6.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
7.	Vasopressins (Vasopressin)
8.	Glucose (Dextrose)
9.	Fluoxetine (Prozac)
10.	Corticotropin-Releasing Hormone

Related Therapies and Procedures

1.	Deep Brain Stimulation